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InTroDuCTIon
Thalassaemias are a major public health 
problem in many parts of the world.1 They 
are a family of inherited disorders of haemo-
globin synthesis characterized by a reduced 
output of one or other of the globin chains of 
adult haemoglobin. The two main disorders 
are transfusion-dependent β-thalassaemia 
major and homozygous α0-thalassaemia. 
Although fetuses affected by homozygous 
α0-thalassaemia usually die in-utero or in 
the early neonatal period, prenatal diag-
nosis is still justified because of maternal 
morbidities, including pre-eclampsia, haem-
orrhage, the adverse psychological impact 
of carrying a hydrops fetalis to term only 
to result in a still-birth, and, occasionally, 
death.2 Homozygous haemoglobin E (HbE) 
is associated with mild anaemia only, 
but coinheritance of β-thalassaemia may 
result in a transfusion-dependent state. The 
coinheritance of the sickle-cell gene and 
β-thalassaemia produces a disease that 
is similar to sickle-cell anaemia. Thalas-
saemia is an autosomal recessive disorder, 
and if both the mother and father carry the 
same thalassaemia trait, their offspring will 
have a 1 in 4 chance of having thalassaemia 
major. The prevalence of different types of 
thalassaemia trait is up to 16% in Cypriot 
populations; 3% to 14% in Chinese and Thai 
populations; 3% to 8% in Indian, Pakistani 
and Bangladedeshi populations; 0.9% in 
black Caribbean and African populations; 
and 0.1% in northern Europeans.3-5
Prenatal screening has been introduced 
worldwide to prevent severe thalassaemias,6-8 
and has shown to be cost-effective in many 
places including the United Kingdom, Quebec, 
Israel and Hong Kong.9-13 The introduction of 
a preventive programme has resulted in a 
marked decline in the number of newborns 
with β-thalassaemia major.14 The choice 
of screening strategy used depends on the 
ethnic origin of the local population, as the 
latter has its own characteristic spectrum 
of haemoglobin variants and thalassaemia 
mutations. Conventionally, prenatal diag-
nosis is performed using amniocentesis or 
chorionic villus sampling (CVS) followed by 
DNA analysis. Compared to the original gene 
mapping method, recently-developed poly-
merase chain reaction (PCR) methods and 
arrays are simpler, faster and less expensive, 
but PCR methods are associated with specific 
diagnostic pitfalls.15 A noninvasive approach 
using serial ultrasound examinations has 
been shown to effectively reduce the need 
for an invasive test in pregnancies unaffected 
by homozygous α0-thalassaemia. Other meth-
ods, including assessment of maternal serum 
markers, maternal plasma fetal erythrocytes, 
maternal plasma fetal DNA, and three- 
dimensional ultrasound examination, have 
been investigated. The aim of the present 
review article is to provide an update on the 
clinical aspects of prenatal screening and 
diagnosis of severe thalassaemias. 
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AnTEnATAl SCrEEnIng
Universal antenatal screening for thalas-
saemia has been advocated for populations 
with a high prevalence of asymptomatic 
thalassaemia trait. With population migra-
tion, thalassaemias are no longer regionally 
specific. Selective prenatal screening tests 
have been offered to at-risk couples because 
of their ethnic origin. Web-based population 
and genetic information on thalassaemia 
mutations and variants is available for easy 
reference.16  
There is no universal screening policy 
which can suit all countries because of the 
heterogeneity of thalassaemias and the 
association with haemoglobin variants in 
different ethnic groups. For populations with 
thalassaemias as the major health problem, 
measurement of maternal mean corpuscular 
volume (MCV) or mean corpuscular haemoglo-
bin (MCH) has been adopted as a screening 
parameter.17 Both MCV and MCH are useful 
as screening for α- and β-thalassaemia traits. 
The choice depends on the familiarity of the 
local laboratory with the measurement of 
each parameter, and whether storage of blood 
before testing for MCV/MCH is required. 
MCH has the theoretical advantage over 
MCV because it is more stable over time. For 
populations with a high prevalence of sickle 
cell and β-thalassaemia traits, haemoglobin 
electrophoresis as well as MCV/MCH should 
be performed for screening because the latter 
is not useful for detecting sickle cell trait. 
Different MCV cutoffs between 76 fL and 
82 fL have been used. By genotyping archived 
samples from schoolchildren with an MCV up 
to 85 fL, it has been shown that a MCV cutoff 
of 80 fL or MCH cutoff of 27 pg could detect 
all Southeast Asia (SEA) deletion carriers and 
β-thalassaemia carriers.18 With MCH, 27 pg 
seems to be the most acceptable cutoff.
Prenatal screening for 
thalassaemia has resulted 
in a marked decline in 
the number of affected 
newborns
If maternal MCV or MCH is found to 
be low, checking the partner’s blood will be 
required. If the partner’s MCV or MCH is also 
low, α0-thalassaemia trait, β-thalassaemia 
trait or iron deficiency need to be excluded 
in both partners.19 Laboratory tests to look 
for the presence of HbH inclusion bodies and 
elevation in HbA2 should be performed, as 
should an iron study. The presence of HbH- 
inclusive inclusion bodies and eleva-
tion of HbA2 (>3.5%) are diagnostic of 
α0-thalassaemia trait and β-thalassaemia, 
respectively. Although normal A2 β- 
thalassaemia exists, it is extremely rare. If 
HbA2 level is normal, HbH inclusion bodies 
are absent, and iron deficiency is detected, 
women should be treated with iron therapy 
first, followed by repeat MCV or MCH 4 
weeks later, before further investigations on 
their thalassaemia status.19 An increase in 
their Hb by 1 g/dL and an increase in MCV 
after iron therapy for 4 weeks can be expected. 
In some ethnic groups such as Cypriots and 
Sardinians, the possibility of δβ-thalassaemia 
should be suspected in women with 
low MCV/MCH who have normal HbA2. 
δβ-thalassaemia and the deletion types of 
hereditary persistence of fetal haemoglobin 
(HPFH) are characterized by an elevated level 
of HbF (5%-30%) in heterozygotes.20 
Couples with confirmed or suspected 
thalassaemia traits are preferably counselled 
by specialists in maternal-fetal medicine or 
specialists with an understanding of prenatal 
diagnosis of thalassaemias. DNA analysis 
will be performed to confirm suspected cases. 
In the presence of a low MCV and a normal 
iron status, absence of HbH inclusion bodies 
does not necessarily exclude α-thalassaemia, 
and DNA analysis is required to detect 
α-thalassaemia trait. Couples carrying 
α0-thalassaemia or β-thalassaemia minor 
have a 1 in 4 chance of having infants 
with homozygous α0-thalassaemia or 
β-thalassaemia major, respectively. For 
couples with discordant thalassaemia traits, 
their fetus will not be at risk of serious 
thalassaemia unless one parent who carries 
β-thalassaemia trait also has coinheritance of 
α0-thalassaemia. In regions with a high prev-
alence of both α- and β-thalassaemia, up to 
7% of β-thalassaemia carriers are compound 
α- and β-thalassaemia heterozygotes,21 
and ζ-mapping should thus be performed 
to exclude α-thalassaemia. If one parent 
has β-thalassaemia trait and the other has 
E-thalassaemia trait, their fetus will have a 
1 in 4 risk of being compound heterozygous 
for β- and E-thalassaemia traits, which can 
be transfusion-dependent in the more severe 
phenotype.  
Early screening allows time for workup 
and counselling for couples who are at risk. 
In case termination of pregnancy needs to be 
considered, timely diagnosis of thalassaemia 
major in the fetus is desirable. For populations 
with a high prevalence of α-thalassaemia 
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carriers, antenatal screening should be 
offered to all pregnant women regardless 
of gestational age, in view of maternal risks 
including pre-eclampsia and postpartum 
haemorrhage. 
Education of healthcare professionals,22 
information for couples and informed consent 
are required before screening. Information for 
couples may be provided through pamphlets, 
videos, websites or explanation in person. 
At-risk couples must be counselled on the 
maternal risks associated with affected 
pregnancies, together with the prognosis, 
available support and treatment for affected 
infants. They also need to be informed of the 
available invasive and noninvasive prenatal 
tests, risk of sampling, limitation and accuracy 
of prenatal tests, screening workflow, and the 
need for confirmation testing at delivery. 
Prenatal screening 
for thalassaemia 
usually includes the 
measurement of maternal 
MCV/MCH with or 
without haemoglobin 
electrophoresis
Screening Pitfalls
If Hb electrophoresis is not performed as part 
of the initial screening, there is a possibility of 
missing some sickle cell carriers or HbE carri-
ers whose MCVs are above 80 fL.23 As a result, 
sickle cell disease (HbS/β-thalassaemia) or 
β-thalassaemia syndrome (β-thalassaemia/
HbE) will be missed if the spouse 
carries β-thalassaemia trait. 
Whether Hb electrophoresis should 
be performed as part of the routine 
screening depends on the preva-
lence of HbE and sickle cell trait in 
a local population and on resources. 
In Hong Kong, Hb electrophoresis 
is not performed routinely because 
HbS is not found in the Chinese 
population.13  
When iron deficiency is accom-
panied by a normal HbA2 level and 
an absence of HbH inclusion bodies, 
the approach of giving iron therapy 
for 4 weeks and then repeating MCV 
measurement before performing 
further investigations on thalas-
saemia status may lead to a delay 
in the prenatal diagnosis of both α- 
and β-thalassaemia. There is a possibility of 
concomitant thalassaemia trait and iron defi-
ciency because in the presence of iron defi-
ciency, HbA2 production may be depressed,24 
and the brilliant cresyl blue preparation used 
for the detection of HbH inclusion bodies may 
be affected. Either DNA analysis to exclude 
the possibility of α0-thalassaemia or serial 
ultrasound examinations to look for features 
of homozygous α0-thalassaemia, as described 
below, should be performed.     
The above antenatal thalassaemia 
screening programmes are not aimed at 
couples who are at risk of having children 
with HbH disease. In α+-thalassaemia carri-
ers (with single α-globin gene deletion or 
nondeletion α-globin gene mutation such as 
Hb Constant Spring), MCV can lie between 
80 fL and 85 fL, and Hb electrophoresis gives 
normal results. The couple will have a chance 
of having a child with HbH disease if the 
spouse carries α0-thalassaemia. However, 
prenatal diagnosis of HbH disease is usually 
not indicated because the affected individual 
is not transfusion-dependent and can enjoy a 
normal life. Rare cases of HbH hydrops fetalis 
have been reported.25,26 It is therefore neces-
sary to determine the type of nondeletion 
α+-thalassaemia mutation of the parent. 
In the presence of a low 
MCV and a normal iron 
status, absence of HbH 
inclusion bodies does 
not necessarily exclude 
α-thalassaemia
There is no universal screening policy 
which can suit all countries because of the 
heterogeneity of thalassaemias and the 
association with haemoglobin variants in 
different ethnic groups.
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PrEnATAl DIAgnoSIS
When at-risk couples are identified, counsel-
ling and prenatal testing should be carried out 
by personnel and laboratories with experience 
in prenatal diagnosis.17 
Prenatal Diagnosis of 
β-thalassaemia Major
As the type of DNA mutations present in each 
individual varies, it is important to know the 
ethnic origin of each partner and allow some 
time for the laboratory to identify the mutation. 
A thalassaemia (thal) array has been designed 
to speed up this process.27 After identification 
of the parental mutations, the fetal diagnosis 
is often accomplished 
by an invasive procedure 
(chorionic villus sampling 
[CVS] or amniocentesis), 
followed by DNA analysis. 
Occasionally, the muta-
tions cannot be identi-
fied, and one may need 
to resort to cordocentesis 
and globin chain assay 
for prenatal diagnosis.28 
However, cordocentesis is 
associated with a 2% risk 
of miscarriage.29
To avoid an invasive 
procedure, examination of 
the circulatory fetal DNA 
in maternal plasma for 
mutant paternal allele has 
been investigated. If pater-
nal mutation is different 
from maternal mutation 
and the former is absent 
from maternal plasma, it will be inferred that 
the fetus has not inherited the mutant pater-
nal allele, and β-thalassaemia major can 
be excluded. However, if paternal mutation 
is present in the maternal plasma, an inva-
sive procedure will still be needed because 
whether the fetus has inherited the maternal 
mutation cannot be determined from exami-
nation of the maternal plasma.30,31 However, 
there are several technical challenges, includ-
ing failure to isolate or extract fetal DNA from 
maternal plasma, or PCR allele dropout.31 The 
use of advanced techniques such as single 
allele base extension reaction and Mass 
ARRAY system may be helpful.31 Further 
studies are needed before this noninvasive 
approach can be used clinically. 
Prenatal diagnosis is 
usually performed by CVS 
or amniocentesis, followed 
by DnA analysis
Prenatal Diagnosis of Homozygous 
α0-thalassaemia
Homozygous α0-thalassaemia can be accu-
rately diagnosed by DNA study of cells 
obtained from CVS or amniocentesis.32 With 
the use of quantitative PCR assay, a report 
can be rapidly available within 1 or 2 days 
after amniocentesis or CVS.33  In areas 
where DNA diagnosis is not easily available, 
the more invasive technique of cordocente-
sis, followed by haemoglobin analysis, is an 
alternative. In affected fetuses, fetal anae-
mia is found, and haemoglobin electropho-
resis shows the presence of Hb Bart’s and 
Hb Portland.
With experienced personnel and a good 
ultrasound machine, serial ultrasound exami-
nations at 12 to 15, 18 to 20, and 30 weeks’ 
gestation can effectively reduce the need for 
invasive testing in the majority of unaffected 
pregnancies.19,34,35 If there is fetal cardio-
megaly (cardiothoracic ratio [CTR] ≥0.50, 
0.52, and 0.59 at 12 to 15, 18 and 30 weeks’ 
gestation, respectively), and/or placento-
megaly (placental thickness >18 mm at 12 
weeks’ gestation), CVS or amniocentesis 
for fetal DNA analysis should be performed 
for confirmation of α0-thalassemia major.19 
On the other hand, if ultrasound examina-
tions are normal, an invasive procedure can 
For couples with α0-thalassaemia, serial ultrasound 
examinations by experienced personnel can reduce the 
need for invasive testing.
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be omitted. This approach is applicable in 
singleton as well as twin pregnancies,36 and 
can be used to confirm normality in pregnan-
cies conceived after preimplantation genetic 
diagnosis.37
Ultrasound Diagnostic Pitfalls
There are several limitations of the non-
invasive approach of using serial ultra-
sound examinations. Firstly, measurement 
of placental thickness may be inaccurate if 
the placenta is adjacent to a focal myome-
trial contraction, or located in the fundus 
or lateral uterine wall. In an affected preg-
nancy, the placenta can be large but its 
thickness can be normal.38 Secondly, the 
predictive values of fetal CTR decrease with 
gestational age.19 In advanced gestation, 
hydropic signs, including ascites and pleural 
effusion, are more apparent than cardio- 
megaly in affected pregnancies.19 Measure-
ment of fetal middle cerebral artery peak 
systolic velocity may be useful.20,39 Thirdly, 
the false-positive rate of this noninvasive 
approach is about 3% because disorders 
such as intrauterine growth restriction, 
congenital heart disease,19 and HbH disease 
can present with cardiomegaly and/or 
placentomegaly. An invasive test is needed 
to confirm the diagnosis of an affected 
fetus. Fourthly, this noninvasive approach 
demands accurate measurement of the fetal 
CTR. Adequate training and subsequent 
quality control are essential. When the 
image quality of the fetal heart at 12 weeks’ 
gestation is suboptimal – even with the use 
of a transvaginal scan – rescanning in 2 to 3 
weeks would be a reasonable option if the 
mother still prefers ultrasound monitoring 
to invasive testing.19 The risk of delaying 
the diagnosis of an affected pregnancy until 
the second trimester and the disadvantages 
of terminating an affected pregnancy in the 
second trimester should be balanced against 
the risk (1%) of invasive testing. 
Other noninvasive methods have been 
investigated. If a woman opts for first trimes-
ter combined Down’s syndrome screening, 
normal maternal serum-free β human chori-
onic gonadotropin (β-hCG) and pregnancy-
associated plasma protein A (PAPP-A) at 11 
to 14 weeks of gestation is a reassuring 
sign of normality for fetuses at risk of homo-
zygous α0-thalassaemia. A high level of free 
β-hCG, however, is not predictive of affected 
fetuses.40 Immunofluorescence staining of 
fetal erythrocytes in maternal blood is a 
potentially useful but labour-intensive non-
invasive technique in the first trimester.41 In 
affected pregnancies, positive staining with 
fluorescence-labelled monoclonal anti-zeta 
(but not with anti-alpha) globin antibodies 
can identify fetal non-nucleated red blood 
cells. More recently, it has become feasible 
to provide a potentially rapid noninvasive 
test using real-time quantitative seminested 
PCR,42 or a multiplex quantitative fluorescent 
PCR (QF-PCR) test.43 The maternal blood is 
examined using simultaneous detection of 
homozygous α0-thalassaemia by the absence 
of both microsatellite markers located within 
breakpoints of the SEA deletion, and exclu-
sion of maternal contamination by the 
absence of noninherited maternal alleles.44 
Laboratory Diagnostic Pitfalls
Most of the errors in diagnosis result from 
maternal contamination, or nonpaternity 
or technical problems of DNA analysis.44 
If prenatal diagnosis of α0-thalassaemia 
is made solely by PCR assay on fetal DNA, 
errors in diagnosis may occur due  to fail-
ure of the PCR assay to generate a specific 
DNA fragment.45 Maternal contamination 
can be reduced by using careful invasive 
techniques, dissecting maternal decidua 
from the fetal trophoblast, and reducing the 
number of amplification cycles to 25.46 If the 
fetal diagnosis is identical to the maternal 
genotype, checking maternal contamination 
by DNA polymorphism analysis to avoid the 
possibility of misdiagnosis will be required. 
ConCluSIonS
Prenatal screening for thalassaemia usually 
includes the measurement of MCV/MCH 
with or without Hb electrophoresis, depend-
ing on the ethnic origin of the local popula-
tion. When at-risk couples are identified, 
counselling and prenatal testing should be 
carried out by personnel and laboratories 
with experience in prenatal diagnosis. Pre-
natal diagnosis is usually performed by CVS 
or amniocentesis, followed by DNA analysis. 
For couples who have α0-thalassaemia, with 
experienced personnel and good ultrasound 
machines, serial ultrasound examination can 
be offered, reserving invasive diagnosis for 
those showing ultrasound features of an 
affected pregnancy. 
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•	 represents	unusual	aspects	of	common	medical	 
conditions;	or
•	 suggests	new	solutions	or	perspectives	upon	 
clinically	relevant	issues.
The report should include a review of published relevant cases, a detailed description of the case, a discussion of why the case is  
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Read the Continuing Medical Education article in this issue, and test your understanding by answering the 
following questions. 
Answers are shown at the bottom of this page. We hope you enjoy learning with JPOG.
CME Article:
Prenatal Diagnosis of Thalassaemia
Answer	True	or	False	to	the	questions	below.
1. Measurement of maternal mean corpuscular volume (MCV) or mean corpuscular haemoglobin 
(MCH) is useful for prenatal screening for thalassaemia.
2. A normal haemoglobin pattern can exclude the possibility of α-thalassaemia.
3. If one parent carries β-thalassaemia trait while the other carries α-thalassaemia, their fetus 
will not be at risk for serious thalassaemia unless the parent who carries β-thalassaemia trait 
has coinheritance of α-thalassaemia.
4. If both the father and the mother carry haemoglobin E trait, their fetus will be at risk of severe 
thalassaemia. 
5. In the presence of iron deficiency, the measurement of haemoglobin A2 production and detec-
tion of haemoglobin H inclusion bodies may be affected.
6. In the prenatal diagnosis of β-thalassaemia major, it is important to know the ethnic origin of 
each partner.
7. In the prenatal diagnosis of homozygous α0-thalassaemia, with the use of quantitative poly-
merase chain reaction assay, a report can be rapidly available within 1 or 2 days after amnio-
centesis or chorionic villus sampling.
8. Serial prenatal ultrasound examinations can effectively reduce the need for invasive testing in 
the majority of pregnancies unaffected by homozygous α0-thalassaemia.
9. Placental thickness is the most useful ultrasonographic parameter in the prediction of preg-
nancies affected by homozygous α0-thalassaemia.
10. In the prenatal diagnosis of thalassaemia, maternal contamination should be suspected if the 
fetal diagnosis is identical to the maternal genotype.
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Answers
 1 2 3 4 5 6 7 8 9 10
 T F T F T T T T F T
